



Bayer AG  
Investor Relations  
51368 Leverkusen  
Germany  
[www.investor.bayer.com](http://www.investor.bayer.com)

## Investor News

---

### **Michael Koenig appointed to the Bayer Board of Management**

Dr. Richard Pott to retire effective June 1, 2013

---

**Leverkusen, Germany, December 14, 2012** – At its meeting today, the Supervisory Board of Bayer AG appointed Michael Koenig (49), currently a member of the Executive Committee of Bayer MaterialScience and Head of the Polycarbonates business unit, to the Board of Management of the holding company effective April 1, 2013. He is to succeed Dr. Richard Pott (59) effective June 1, 2013, upon Pott's retirement as of that date. Pott has worked for Bayer since 1984 and has been a member of the Board of Management since May 1, 2002. Koenig will take over Pott's duties as Labor Director and as the Board member responsible for human resources, the Latin America, Africa and Middle East regions and the subsidiary Currenta. As part of the reorganization within the Board of Management, the Chairman, Dr. Marijn Dekkers, will assume responsibility for strategy and Chief Financial Officer Werner Baumann will additionally look after the North America region from the middle of next year.

"Michael Koenig is a successful and experienced manager with proven expertise in production, technology and marketing," commented Werner Wenning, Chairman of the Supervisory Board of Bayer AG. "In addition, he has lived and worked in China for many years and thus has great experience of this market, which is very important for Bayer."

The future Management Board member was born in Iserlohn, Germany, on September 3, 1963. Koenig studied chemical process engineering at TU Dortmund University.

He began his career at Bayer AG in 1990 as a process engineer for chemicals projects in Europe. After serving in positions of increasing responsibility, he transferred to China in 2000 to become General Manager of Bayer Polymers Shanghai Co. Ltd. There he led the first negotiations on the construction of the new production site, the Bayer Integrated Site Shanghai, and was made site manager in 2002.

Having first served as Global Head of Production and Technology Isocyanates at Bayer MaterialScience, Koenig became Senior Bayer Representative for the Greater China country group and Senior Country Representative for Bayer MaterialScience in China on April 1, 2007. He has been Head of Bayer MaterialScience's Polycarbonates business unit, headquartered in Shanghai, since July 1, 2011. In his function as a member of the Executive Committee of Bayer MaterialScience, he also holds responsibility for the Asia/Pacific region.

Koenig is married and has two children.

**Dr. Richard Pott** has been a member of the Bayer AG Board of Management since May 1, 2002. He is currently responsible for strategy and human resources and is the company's Labor Director. He also looks after the Americas, Africa and Middle East regions.

Pott was born in Leverkusen-Opladen, Germany, on May 11, 1953. Having obtained a doctorate in physics at the University of Cologne, he joined Bayer's Central Research Division in Krefeld-Uerdingen, Germany, in 1984. He transferred to the Corporate Staff Division in 1987, working first as an organization consultant in the Corporate Organization Department and then, starting in 1989, as a strategic consultant in the Strategic Planning department. Three years later, Pott became Head of Strategic Planning.

On May 1, 1997, he was appointed Head of the Corporate Planning and Controlling Division. On July 1, 1999, he became General Manager of the Specialty Products Business Group, a position he held until his appointment to the Board of Management three years later.

Pott is married and has three children.

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)

Dr. Juergen Beunink (+49-214-30-65742)

Peter Dahlhoff (+49-214-30-33022)

Judith Nestmann (+49-214-30-66836)

Dr. Olaf Weber (+49-214-30-33567)

Fabian Kligen (+49-214-30-35426)

**Forward-Looking Statements**

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at [www.bayer.com](http://www.bayer.com). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.